A population pharmacokinetic approach to ceftazidime use in burn patients: influence of glomerular filtration, gender and mechanical ventilation

被引:39
作者
Conil, Jean Marie
Georges, Bernard
Lavit, Michel
Laguerre, Jacky
Samii, Kamram
Houin, Georges
Saivin, Sylvie
机构
[1] Inst Federatif Biol, Lab Pharmacocinet & Toxicol Clin, F-31059 Toulouse 9, France
[2] Hop Rangueil, Serv Reanimat, Toulouse, France
[3] Fac Sci Pharmaceut Toulouse, UPTE INRA ENVT, UMR 181, Lab Cinet Xenobiot, F-31400 Toulouse, France
[4] Hop Rangueil, Serv Brules, Toulouse, France
关键词
burn patients; ceftazidime; population pharmacokinetics; MAJOR BURNS; CLINICAL PHARMACOKINETICS; ANTIBACTERIAL ACTIVITY; SERUM CREATININE; RENAL-FUNCTION; PREDICTION;
D O I
10.1111/j.1365-2125.2007.02857.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims The aim of this study was to evaluate the disposition of ceftazidime in burn patients using a population pharmacokinetic approach, and to identify the clinical and biological parameters influencing its pharmacokinetics. Methods The development of the pharmacokinetic model was based on 237 serum ceftazidime concentrations from 50 burn patients. The determination of the pharmacokinetic parameters and the selection of covariates were performed using a nonlinear mixed-effect modelling method. Results A two-compartment model with first order elimination incorporating a proportional error model best fitted the data. Ceftazidime clearance (CL, l h(-1)) was significantly correlated with creatinine clearance (CLCR), and the distribution volume of the peripheral compartment (V2, l) was correlated with gender, mechanical ventilation and the CLCR. The final model was defined by the following equations: CL = 1 08 + 0.0536 x CLCR Q (intercompartmental clearance) = 6.881 1h(-1) V1 (distribution volume of the central compartment) - 18.81 V2 = 2.69 x (1 + 1.43 x SEX) x (1 + 2.44 x VENT) x (1 + 0.00414 x CLCR) Ceftazidime clearance was 6.1 and 5.7 l h(-1) for mechanically ventilated males and females, respectively, and 7.2 and 6.6 l h(-1) for nonventilated patients. The total volume of distribution was 31.6 and 49.4 l for mechanically ventilated males and females, respectively, and 22.8 and 28.1 l h (-1)for nonventilated patients. Conclusions We have shown that gender, mechanical ventilation and CLCR significantly influence the disposition of ceftazidime in burn patients. Interindividual variability in the pharmacokinetics of ceftazidime was significant and emphasizes the need for therapeutic monitoring.
引用
收藏
页码:27 / 35
页数:9
相关论文
共 24 条
  • [1] EFFECT OF PEEP VENTILATION ON RENAL-FUNCTION, PLASMA-RENIN, ALDOSTERONE, NEUROPHYSINS AND URINARY ADH, AND PROSTAGLANDINS
    ANNAT, G
    VIALE, JP
    XUAN, BB
    AISSA, OH
    BENZONI, D
    VINCENT, M
    GHARIB, C
    MOTIN, J
    [J]. ANESTHESIOLOGY, 1983, 58 (02) : 136 - 141
  • [2] BAUX S, 1955, THESIS PARIS
  • [3] BEAL SL, 1982, CRIT REV BIOMED ENG, V8, P195
  • [4] Clinical pharmacokinetics of piperacillin-tazobactam combination in patients with major burns and signs of infection
    Bourget, P
    LesneHulin, A
    LeReveille, R
    LeBever, H
    Carsin, H
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (01) : 139 - 145
  • [5] PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE
    COCKCROFT, DW
    GAULT, MH
    [J]. NEPHRON, 1976, 16 (01) : 31 - 41
  • [6] CONIL J, 2006, IN PRESS INT J CLIN
  • [7] Population pharmacokinetics of ceftazidime in burn patients
    Dailly, E
    Pannier, M
    Jolliet, P
    Bourin, M
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 56 (06) : 629 - 634
  • [8] Assessment of renal function in recently admitted critically ill patients with normal serum creatinine
    Hoste, EAJ
    Damen, J
    Vanholder, RC
    Lameire, NH
    Delanghe, JR
    Van den Hauwe, K
    Colardyn, FA
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 (04) : 747 - 753
  • [9] KELLEN M, 1994, ANESTH ANALG, V78, P134
  • [10] Clinical pharmacokinetics of ciprofloxacin in patients with major burns
    Lesne-Hulin, A
    Bourget, P
    Ravat, F
    Goudin, C
    Latarjet, J
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 55 (07) : 515 - 519